drugset / Trial / NCT05525208
Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Phase 2
Completed
696 enrolled
PT Bio Farma
Udayana University · collabUniversitas Padjadjaran · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Observer-blind, randomized, active-controlled prospective intervention study of Immunogenicity \& Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-07-02
- Completion
- 2023-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT162b2 | Messenger RNA (mRNA) | — | — |
| Subject | SARS-CoV-2 RBD subunit recombinant protein | Vaccine | — | — |